Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 196

1.

Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC.

Hunault CC, Mensinga TT, de Vries I, Kelholt-Dijkman HH, Hoek J, Kruidenier M, Leenders ME, Meulenbelt J.

Psychopharmacology (Berl). 2008 Dec;201(2):171-81. doi: 10.1007/s00213-008-1260-2. Epub 2008 Aug 10.

PMID:
18695931
2.

Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC).

Hunault CC, Mensinga TT, Böcker KB, Schipper CM, Kruidenier M, Leenders ME, de Vries I, Meulenbelt J.

Psychopharmacology (Berl). 2009 May;204(1):85-94. doi: 10.1007/s00213-008-1440-0. Epub 2008 Dec 20.

PMID:
19099294
3.

Acute subjective effects after smoking joints containing up to 69 mg Δ9-tetrahydrocannabinol in recreational users: a randomized, crossover clinical trial.

Hunault CC, Böcker KB, Stellato RK, Kenemans JL, de Vries I, Meulenbelt J.

Psychopharmacology (Berl). 2014 Dec;231(24):4723-33. doi: 10.1007/s00213-014-3630-2. Epub 2014 May 31.

PMID:
24879495
4.

Disposition of smoked cannabis with high Δ(9)-tetrahydrocannabinol content: a kinetic model.

Hunault CC, van Eijkeren JC, Mensinga TT, de Vries I, Leenders ME, Meulenbelt J.

Toxicol Appl Pharmacol. 2010 Aug 1;246(3):148-53. doi: 10.1016/j.taap.2010.04.019. Epub 2010 May 4.

PMID:
20450927
5.

Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence.

Milman G, Bergamaschi MM, Lee D, Mendu DR, Barnes AJ, Vandrey R, Huestis MA.

Ther Drug Monit. 2014 Apr;36(2):218-24. doi: 10.1097/FTD.0b013e3182a5c446.

6.

Cannabis with high δ9-THC contents affects perception and visual selective attention acutely: an event-related potential study.

Böcker KB, Gerritsen J, Hunault CC, Kruidenier M, Mensinga TT, Kenemans JL.

Pharmacol Biochem Behav. 2010 Jul;96(1):67-74. doi: 10.1016/j.pbb.2010.04.008. Epub 2010 Apr 24.

PMID:
20417659
7.

Psychomotor performance, subjective and physiological effects and whole blood Δ⁹-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis.

Schwope DM, Bosker WM, Ramaekers JG, Gorelick DA, Huestis MA.

J Anal Toxicol. 2012 Jul;36(6):405-12. doi: 10.1093/jat/bks044. Epub 2012 May 15.

8.

Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint.

Fabritius M, Chtioui H, Battistella G, Annoni JM, Dao K, Favrat B, Fornari E, Lauer E, Maeder P, Giroud C.

Anal Bioanal Chem. 2013 Dec;405(30):9791-803. doi: 10.1007/s00216-013-7412-1. Epub 2013 Nov 8.

PMID:
24202191
9.
10.
11.

Cognition and motor control as a function of Delta9-THC concentration in serum and oral fluid: limits of impairment.

Ramaekers JG, Moeller MR, van Ruitenbeek P, Theunissen EL, Schneider E, Kauert G.

Drug Alcohol Depend. 2006 Nov 8;85(2):114-22. Epub 2006 May 24.

PMID:
16723194
12.

Comparison of Cannabinoid Concentrations in Plasma, Oral Fluid and Urine in Occasional Cannabis Smokers After Smoking Cannabis Cigarette.

Marsot A, Audebert C, Attolini L, Lacarelle B, Micallef J, Blin O.

J Pharm Pharm Sci. 2016 Jul - Sep;19(3):411-422. doi: 10.18433/J3F31D.

13.

Extended plasma cannabinoid excretion in chronic frequent cannabis smokers during sustained abstinence and correlation with psychomotor performance.

Karschner EL, Swortwood MJ, Hirvonen J, Goodwin RS, Bosker WM, Ramaekers JG, Huestis MA.

Drug Test Anal. 2016 Jul;8(7):682-9. doi: 10.1002/dta.1825. Epub 2015 Jun 11.

14.
15.
16.

[Time profile of serum THC levels in occasional and chronic marihuana smokers after acute drog use - implication for drivind motor vehicles].

Balíková M, Hložek T, Páleníček T, Tylš F, Viktorinová M, Melicher T, Androvičová R, Tomíček P, Roman M, Horáček J.

Soud Lek. 2014;59(1):2-6. Czech.

PMID:
24625019
17.

Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study.

van der Pol P, Liebregts N, Brunt T, van Amsterdam J, de Graaf R, Korf DJ, van den Brink W, van Laar M.

Addiction. 2014 Jul;109(7):1101-9. doi: 10.1111/add.12508. Epub 2014 Mar 17.

PMID:
24628797
18.

Psychomotor performance in relation to acute oral administration of Delta9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects.

Roser P, Gallinat J, Weinberg G, Juckel G, Gorynia I, Stadelmann AM.

Eur Arch Psychiatry Clin Neurosci. 2009 Aug;259(5):284-92. doi: 10.1007/s00406-009-0868-5. Epub 2009 Feb 17.

PMID:
19224107
19.

Evaluation of Δ(9) -tetrahydrocannabinol detection using DrugWipe5S(®) screening and oral fluid quantification after Quantisal™ collection for roadside drug detection via a controlled study with chronic cannabis users.

Wille SM, Di Fazio V, Toennes SW, van Wel JH, Ramaekers JG, Samyn N.

Drug Test Anal. 2015 Mar;7(3):178-86. doi: 10.1002/dta.1660. Epub 2014 Apr 21.

PMID:
24753449
20.

The safety of modafinil in combination with oral ∆9-tetrahydrocannabinol in humans.

Sugarman DE, Poling J, Sofuoglu M.

Pharmacol Biochem Behav. 2011 Mar;98(1):94-100. doi: 10.1016/j.pbb.2010.12.013. Epub 2010 Dec 21.

Supplemental Content

Support Center